Europe vs US Biosimilar Markets: A 2026 Comparison

Imagine two massive engines running on the same fuel but tuned for completely different speeds. That is exactly what is happening in the global biosimilar market right now. One engine, Europe, has been humming steadily since 2006, creating a mature ecosystem where doctors and patients are comfortable with these high-quality, lower-cost alternatives to expensive biologic drugs. The other engine, the United States, spent years sputtering due to legal roadblocks and complex regulations, but it is now revving up at breakneck speed as billions of dollars in patent protections expire.

If you are trying to understand why drug prices vary so wildly between continents or where the next big opportunities lie in healthcare, you need to look past the generic pills and into the world of biologics. These aren't simple chemical copies; they are complex living products. And the race to make them accessible is reshaping the entire pharmaceutical landscape.

The Core Difference: Maturity vs. Momentum

To get this straight, we have to look at the timeline. Europe started this journey nearly two decades ago. In 2006, the European Medicines Agency (EMA) approved Omnitrope, the world’s first biosimilar. This early start allowed Europe to build a "virtuous cycle," as Dr. Michael Reilly from Alira Health puts it. Physicians got used to prescribing them, payers got used to reimbursing them, and patients got used to taking them. By 2024, the European biosimilar market was valued at roughly USD 13.16 billion, growing at a steady compound annual growth rate (CAGR) of 13% from 2020.

The United States took a much slower path. Even though the Biologics Price Competition and Innovation Act (BPCIA) was passed in 2009, the first US biosimilar, Zarxio, didn’t hit the market until March 2015. Why the delay? Legal warfare. Originator companies-those who made the original expensive drugs-used "patent thickets" and the confusing "patent dance" rules to block competitors. As a result, while Europe had over 100 approved biosimilars by 2024, the US had launched only about 12. However, the momentum has shifted. The US market reached USD 10.9 billion in 2024 and is projected to grow at a blistering 18.5% CAGR through 2033. The US isn't just catching up; it is accelerating because the sheer size of its biologics market is finally opening up.

Regulatory Roadblocks and Recent Breakthroughs

The biggest reason for the divergence between these two markets is how regulators view proof of safety. For years, the US Food and Drug Administration (FDA) required extensive clinical trials and, crucially, "switching studies" to grant a biosimilar "interchangeable" status. Interchangeability meant a pharmacist could swap the brand-name drug for the biosimilar without the doctor calling in a new prescription. Those switching studies were expensive and time-consuming, acting as a huge barrier to entry.

Europe took a different approach. The EMA uses a "totality-of-evidence" method. They rely heavily on analytical data-comparing the molecular structure of the new drug to the old one-rather than demanding massive new clinical trials if the science shows the molecules are nearly identical. Dr. Hans-Georg Eichler of the EMA argues that robust scientific evaluation is more effective than redundant clinical trials.

Here is the game-changer for 2026: In June 2024, the FDA proposed new guidelines that effectively eliminate the requirement for switching studies to achieve interchangeable designation. This is a massive shift toward the European model. Dr. Rachel Sherman of the FDA acknowledged that previous requirements created unnecessary barriers. This change alone is expected to flood the US market with new options, particularly in areas like oncology and rheumatology, where interchangeability drives adoption.

The Patent Cliff: A 2 Billion Opportunity

Why is everyone suddenly talking about biosimilars? Because the golden age of blockbuster biologics is ending. Between 2025 and 2034, 118 major biologics are expected to lose their patent protection. According to IQVIA, this represents a staggering $232 billion opportunity for biosimilar manufacturers.

In Europe, the uptake has already happened in key therapeutic areas. In countries like Germany and France, biosimilars hold over 80% market share in some oncology and rheumatology treatments. Hospital tenders-where hospitals bid for the lowest price to supply drugs-accelerated this adoption. Germany, in particular, has become a manufacturing powerhouse, attracting global developers.

The US is now facing its own patent cliffs. The most famous example is Humira (adalimumab). When its patent expired, 14 biosimilars were approved in the US. However, due to patent settlements and litigation, only six were commercially available for a long time. Now, with the regulatory winds changing and the Inflation Reduction Act of 2022 providing incentives for Medicare to adopt biosimilars, the US is poised for a similar explosion in market share. The US advantage is scale: it has a larger pool of high-revenue biologics coming off-patent than any other region.

Who Wins? Future Projections and Market Dynamics

So, which market will dominate? It depends on how you measure "dominate." If you look at current revenue, Europe still holds the lead in terms of established infrastructure and volume. But if you look at growth velocity, the US is winning.

Precedence Research projects that North America will overtake Europe in regional market revenue by 2027, reaching approximately USD 17.2 billion. The global market itself is exploding, with estimates ranging from USD 136 billion to USD 175 billion by the early 2030s. The US market is expected to reach USD 30.2 billion by 2033, driven by an 18.5% CAGR. Europe is also growing fast, at a 17.34% CAGR, reaching USD 64.82 billion by 2034 according to some models, though methodologies vary between research firms.

The key difference lies in the healthcare systems. Europe’s centralized pricing and mandatory substitution policies create ideal conditions for rapid uptake. The US system is fragmented, involving private payers, CMS coverage decisions, and hospital formularies. However, the financial pressure on US healthcare providers is forcing a faster embrace of biosimilars. With biosimilars typically launching at a 15-30% discount compared to reference products, the savings are too significant to ignore for cash-strapped hospitals and insurers.

Therapeutic Focus: Where Are Biosimilars Used?

You won't find biosimilars everywhere yet. Their adoption follows the complexity of the drug.

• Supportive Care: This was the low-hanging fruit. Drugs like filgrastim (used to boost white blood cell counts during chemotherapy) were among the first biosimilars in both regions. They are relatively simple molecules.
• Oncology and Rheumatology: Europe leads here. Monoclonal antibodies used to treat cancer and autoimmune diseases are complex, but European doctors have normalized their use. The US is rapidly following suit as interchangeability rules ease.
• Endocrinology: Insulin analogs and growth hormones are seeing increased competition, helping to address chronic affordability issues.

The next frontier involves highly complex molecules, such as those targeting multiple pathways simultaneously. Both the FDA and EMA are working on frameworks to evaluate these, but the bar for evidence remains higher. Manufacturing these drugs is difficult; a slight change in temperature or pH during production can alter the molecule's efficacy. This is why manufacturing expertise, particularly in hubs like Germany, remains a critical competitive advantage.

Challenges Ahead

Despite the optimism, hurdles remain. Physician education is still needed. Many doctors trained when biosimilars were rare are hesitant to switch patients from a brand they know to a new product, even if the science supports it. Patient acceptance is another factor; some patients fear that "similar" means "inferior," despite rigorous regulatory oversight proving otherwise.

Additionally, the supply chain for biologics is fragile. Unlike small-molecule generics that can be produced in many facilities, biologics require specialized, sterile environments. Any disruption in raw materials or manufacturing can impact availability. As the market grows, ensuring a stable supply chain will be just as important as regulatory approval.